Summary
GBI Research has released its research - “The Future of Pain Management Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Generic Competition Creates Challenges”. The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global pain management therapeutics market. The report analyzes the markets for pain management in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
http://www.visionshopsters.com/
Scope
The scope of this report includes:
- Annualized market data for the pain management market from 2001 to 2009, forecast forward to 2016.
- Analysis of the leading therapeutic segments, including neuropathic pain, osteoarthritis, cancer pain, migraine and fibromyalgia.
- Analysis of the pain management market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the pain management market including market size, the annual cost of therapy, sales volume and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in the various phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer, Inc., Eli Lilly and Company, Johnson & Johnson, Novartis AG, Merck & Co Inc., and Cephalon, Inc.
- Key M&A activities that have taken place in 2009 and the licensing agreements in the 2008-2009 global pain management market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to
- Align product portfolio to the markets with high growth potential
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
- Develop key strategic initiatives by understanding key focus areas of leading companies
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps
Companies Mentioned
Pfizer, Inc.
Eli Lilly and Company
Johnson & Johnson
Endo Pharmaceuticals
Novartis AG
Merck & Co Inc
Cephalon, Inc.
To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/
Contact us:
Visionshopsters
Ph : 91-22-40583000
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com
